PL3986419T3 - Pochodne kwasu boronowego i ich zastosowania terapeutyczne - Google Patents

Pochodne kwasu boronowego i ich zastosowania terapeutyczne

Info

Publication number
PL3986419T3
PL3986419T3 PL20827883.8T PL20827883T PL3986419T3 PL 3986419 T3 PL3986419 T3 PL 3986419T3 PL 20827883 T PL20827883 T PL 20827883T PL 3986419 T3 PL3986419 T3 PL 3986419T3
Authority
PL
Poland
Prior art keywords
acid derivatives
boronic acid
therapeutic applications
therapeutic
applications
Prior art date
Application number
PL20827883.8T
Other languages
English (en)
Inventor
Olga Lomovskaya
Original Assignee
Qpex Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qpex Biopharma, Inc. filed Critical Qpex Biopharma, Inc.
Publication of PL3986419T3 publication Critical patent/PL3986419T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20827883.8T 2019-06-19 2020-06-17 Pochodne kwasu boronowego i ich zastosowania terapeutyczne PL3986419T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962863752P 2019-06-19 2019-06-19
PCT/US2020/038171 WO2020257306A1 (en) 2019-06-19 2020-06-17 Boronic acid derivatives and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
PL3986419T3 true PL3986419T3 (pl) 2025-09-08

Family

ID=74040882

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20827883.8T PL3986419T3 (pl) 2019-06-19 2020-06-17 Pochodne kwasu boronowego i ich zastosowania terapeutyczne

Country Status (13)

Country Link
US (1) US20230144152A1 (pl)
EP (2) EP3986419B1 (pl)
CN (1) CN114340639A (pl)
DK (1) DK3986419T3 (pl)
ES (1) ES3036963T3 (pl)
FI (1) FI3986419T3 (pl)
HR (1) HRP20250815T1 (pl)
HU (1) HUE072159T2 (pl)
LT (1) LT3986419T (pl)
PL (1) PL3986419T3 (pl)
PT (1) PT3986419T (pl)
SI (1) SI3986419T1 (pl)
WO (1) WO2020257306A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109415386B (zh) 2016-06-30 2022-04-19 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
WO2019204419A1 (en) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
JP2023524525A (ja) 2020-05-05 2023-06-12 キューペックス バイオファーマ, インコーポレイテッド ボロン酸誘導体、ならびにその合成、多形体、および治療的使用
EP4319760A4 (en) * 2021-04-05 2025-01-08 Qpex Biopharma, Inc. CEFTIBUTENE DOSAGE REGIMEN
JP2026504522A (ja) * 2023-02-08 2026-02-05 キューペックス バイオファーマ, インコーポレイテッド シデロフォアベータ-ラクタムの感受性を決定するための方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
CA2705389A1 (en) 2007-11-13 2009-05-22 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9687497B1 (en) * 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2017100537A1 (en) * 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN109415386B (zh) * 2016-06-30 2022-04-19 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
WO2018075084A1 (en) 2016-10-20 2018-04-26 Symbol Technologies, Llc Mobile device with edge activation
BR112020007138B1 (pt) * 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos

Also Published As

Publication number Publication date
TW202114706A (zh) 2021-04-16
HUE072159T2 (hu) 2025-10-28
EP3986419A4 (en) 2023-07-12
DK3986419T3 (da) 2025-08-04
EP3986419B1 (en) 2025-05-14
CN114340639A (zh) 2022-04-12
EP4599892A3 (en) 2025-09-10
LT3986419T (lt) 2025-08-25
PT3986419T (pt) 2025-07-31
EP4599892A2 (en) 2025-08-13
HRP20250815T1 (hr) 2025-09-12
WO2020257306A1 (en) 2020-12-24
US20230144152A1 (en) 2023-05-11
SI3986419T1 (sl) 2025-09-30
FI3986419T3 (fi) 2025-07-24
EP3986419A1 (en) 2022-04-27
ES3036963T3 (en) 2025-09-25

Similar Documents

Publication Publication Date Title
DK3478693T3 (da) Boronsyrederivater og terapeutiske anvendelser deraf
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
PL3986419T3 (pl) Pochodne kwasu boronowego i ich zastosowania terapeutyczne
EP3781576C0 (en) BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
DK3565550T3 (da) Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan
IL277640A (en) Humanized bcma antibody and bcma-car-t cells
PL4234581T3 (pl) Przeciwciała terapeutyczne i ich zastosowania
HUE052468T2 (hu) Arginázgátlók és terápiás alkalmazásaik
IL291191A (en) Cdk inhibitors and their use as pharmaceuticals
LT4331584T (lt) Lanifibranoro deuterintų darinių terapietiniai naudojimai
PL3555076T3 (pl) Nowe pochodne kwasu fenylopropionowego i ich zastosowania
DK3786160T3 (da) Pyridinderivater og terapeutiske anvendelser deraf som trpc6-inhibitorer
HUE036672T2 (hu) Pirazol-amid vegyület és gyógyászati alkalmazásai
DK3514153T3 (da) Pyrimidinforbindelse og farmaceutisk anvendelse deraf
DK3255042T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme
PL3618848T3 (pl) Biologicznie aktywne kompleksy i ich zastosowania terapeutyczne
EP3750553A4 (en) THERAPEUTIC FOR PSORIASIS
DK3615514T3 (da) Propionsyre-derivater og deres anvendelsesformål
EP3526186A4 (en) SUBSTITUTED HYDROXY STYLENE AND THEIR THERAPEUTIC APPLICATIONS
IL263506A (en) Topical formulations of pde-4 inhibitors and their methods of use
DK2958573T3 (da) Farmaceutiske formuleringer af nitrit og anvendelser deraf
DK3919498T6 (da) Pyrrolopyrimidinderivat og anvendelse deraf
EP3601223A4 (en) ISOTOPE-ENRICHED 3-AMINO-1-PROPANESULPHONIC ACID DERIVATIVES AND THEIR USES
PL3452441T3 (pl) Pochodne kwasu alfa-truksylowego i ich kompozycje farmaceutyczne